Financial Performance - 3Q25 revenue reached $60.2 million, exceeding the high-end of the guidance range of $56 million to $59 million[8] - Adjusted EBITDA for 3Q25 was $4.8 million, also surpassing the high-end of the guidance range of $(4) million to $(2) million[8] - Recurring revenue accounted for 92% of total revenue in 3Q25, amounting to $55.1 million[8] - The company anticipates adjusted EBITDA to exceed Capex in FY25[8] Customer Metrics - The average revenue per customer (ARPC) increased to $665,000 in 3Q25[16] - Net revenue retention rate for recurring revenue was 78% in 3Q25[16] - Remaining performance obligations stood at $197 million in 3Q25[16] Guidance - 4Q25 revenue is projected to be between $50.5 million and $55.5 million, representing a year-over-year decline of (31)% to (24)%[19] - Full year 2025 revenue is guided to be in the range of $235 million to $240 million, a year-over-year decrease of (25)% to (23)%[19] - Adjusted EBITDA for 4Q25 is expected to be between $(0.3) million and $4.7 million, with a margin of (0.6)% to 8.5%[19] - Full year 2025 adjusted EBITDA is projected to be between $7.5 million and $12.5 million, with a margin of 3.2% to 5.2%[19]

THIRD QUARTER 2025 BUSINESS UPDATE This communication contains "forward-looking statements" that are not historical facts, and involve risks and uncertainties that could cause actual results of AST SpaceMobile to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "would," "potential," "projects," "predicts," ...

Financial Performance - Q3 2025 revenue reached $123.3 million, a 21.6% year-over-year increase[16] - Q3 2025 gross margin improved to 37.6%, a 4.4 percentage point increase year-over-year[16] - Q3 2025 adjusted net profit was $11.9 million[18,50] - Q3 2025 adjusted EBITDA was $21.9 million[20,50] - The company ended the period with $143 million in cash, including restricted cash, a $33 million increase[59] Business Development and Strategy - The company established a partnership with Škoda Group to develop battery systems for rail applications, with the first prototype expected by the end of 2026[44] - The company is expanding its Huzhou facility with Phase 3.2, expected to provide an additional 2 GWh of capacity annually, with initial production anticipated in Q1 2026[28,33] - The company is focused on product innovation, market capture, and capacity expansion[23,24] Outlook - The company projects revenue growth of 18-25% for 2025, with revenue guidance of $450-475 million[63,64] - The company is targeting a gross margin range of 32%-35% for 2025[65] - The company anticipates over 50% year-over-year revenue growth in the Americas for 2025[67]

3Q 2025 Earnings Presentation November 2025 FORWARD- LOOKING STATEMENTS Statements made in this presentation regarding American Public Education, Inc. or its subsidiary institutions ("APEI" or the "Company") that are not historical facts are forward-looking statements based on current expectations, assumptions, estimates and projections about APEI and the industry. In some cases, forward looking statements can be identified by words such as "anticipate," "believe," "seek," "could," "estimate," "expect," "in ...

November 10, 2025 Earnings Conference Call Q3 2025 Safe Harbor | Note Regarding Forward-Looking Information This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of management of Identiv and can be identified by words such as "anticipate," "believe," "continue," "plan," ...

Q3`25 Review Nov 10, 2025 Q3'25 Fold Holdings, Inc. Company highlights Disclaimer Forward looking statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally relate to future events or the Company's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which the Company operates and anticipated growth in demand for the Company's products and servic ...

Investor Presentation November 2025 © 2025 ON24, Inc. | Confidential Legal Disclaimer This presentation contains "forward-looking statements" under applicable securities laws. Such statements can be identified by words such as: "outlook," "expect," "convert," "believe," "plan," "future," "may," "should," "will," and similar references to future periods. Forward-looking statements include express or implied statements regarding our expected financial and operating results, the execution of our capital return ...

CoreWeave Q3'25 Earnings Presentation November 10, 2025 1 2 Q3'25 at a Glance STRONG REVENUE TRAJECTORY Q1' 25 QoQ Revenue $1.4 billion ADJUSTED EBITDA3 ADJUSTED OPERATING INCOME3 61% Margin $838 million $217 million 16% Margin up 134% YoY STRONG REVENUE TRAJECTORY REVENUE BACKLOG1 $55.6 billion up 271% YoY REVENUE STRONG REVENUE TRAJECTORY CAPITAL EXPENDITURES 2 $1.9 billion $(41) million (3)% Margin ADJUSTED NET INCOME (LOSS) 3 Forward-Looking Statements This presentation contains "forward-looking stateme ...

The statements in this presentation regarding expectations of future events or results, including SI-BONE's expectations of continued revenue and procedure growth and financial outlook, are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement fo ...

Vilastobart Clinical Data and Opportunity - Vilastobart, in combination with atezolizumab, showed a 40% Overall Response Rate (ORR) in MSS mCRC patients without liver metastases and with high plasma TMB[30, 42] - 63% of plasma TMB-evaluable patients had high plasma TMB (≥10 mutations/Mb) in the Phase 2 trial, including all TMB-evaluable responders[32, 33, 42] - A statistically significant correlation (p=0.05) was observed between plasma TMB status and response to vilastobart plus atezolizumab[33, 42] - The combination of vilastobart and atezolizumab demonstrated a differentiated safety profile, with a low discontinuation rate of 5% and only 7% of patients experiencing colitis of any grade[35, 36, 42] Market and Competitive Landscape - Approximately 95% of mCRC patients are MSS, and standard of care in 3L+ provides minimal benefit (1-6% ORR)[23] - Real-world data indicates that approximately 55% of patients with MSS CRC have high plasma TMB, which is substantially higher than historically reported with tissue-based TMB assays[28, 42] - Next-generation anti-CTLA-4 agents in development show promising clinical efficacy in MSS mCRC, with ORRs ranging from 8-29% and discontinuation rates due to AEs up to ~30%[21] Technology and Pipeline - Xilio's clinically-validated platform technology is being applied across diverse mechanisms and architectures, including antibodies, cytokines, bispecifics, and T cell engagers[13, 14] - Efarindodekin Alfa (tumor-activated IL-12) demonstrated promising clinical efficacy with a generally well-tolerated safety profile in Phase 1 in patients with advanced solid tumors[44] - Masked T cell engager programs demonstrated potent anti-tumor activity with favorable tolerability across a diverse range of targets in preclinical models[50, 51, 52] Financial Outlook and Milestones - The company anticipates a cash runway into Q1 2027, including a $175 million development milestone received under the Gilead license in Q4 2025[53] - Anticipated milestones include reporting updated Phase 2 data for vilastobart in combination with atezolizumab in metastatic MSS mCRC in 1H 2026 and IND submissions for at least two masked T cell engager programs in 2027[53]